Insmed is a global biopharmaceutical company delivering transformative therapies for patients with serious and rare diseases. The company approaches drug development through the lens of patient need, making every decision as if a patient were in the room. With approved medicines and investigational treatments for bronchiectasis and pulmonary arterial hypertension, Insmed advances science across four global research centres. Founded in 1988 and publicly traded, Insmed operates with a people-first culture recognised as Science magazine's number one top employer for five consecutive years. Over 1,500 team members combine expertise in gene therapy and protein engineering to deliver life-altering medicines to patients with unmet medical needs.
1500
Team Members
1988
Founded
Pharma
Sector
Hybrid
Work Environment
A world where patients with serious and rare diseases have access to life-altering therapies that transform their lived experiences and restore possibilities once thought out of reach
Insmed's mission is to transform the lives of patients with serious and rare diseases